Global Market Study on Influenza Diagnostics: Increasing Availability of Rapid Influenza Diagnostic Tests Aiding Market Growth

Influenza Diagnostics  Market
  • Published On : May-2020 |
  • Pages : 239 Pages |
  • Format : Influenza Diagnostics  Market Influenza Diagnostics  Market Influenza Diagnostics  Market Influenza Diagnostics  Market

The U.S. Centers for Disease Control (CDC) tracked 7 million flu cases in the U.S. in 2019, prompting tens of thousands of hospitalizations and concerns among high risk populations. However, the high risk population for influenza consists of pregnant women, children, elderly population, healthcare workers, and immunosuppressed patients that suffer from chronic medical conditions. Seasonal flu is a serious disease that infects a large population and causes serious illness, resulting in large number of hospitalizations and deaths every year. This factor is increasing the demand for faster diagnosis and driving the growth of the influenza diagnostics market.

Influenza V/S. COVID-19 - Similarities and Differences

According to the Centers for Disease Control (CDC), influenza testing across the United States is higher than normal because of the COVID-19 pandemic. A similarity in influenza and COVID-19 is that, both cause respiratory issues. Additionally, both viruses are transmitted by contact fomites and droplets. Moreover, the first stage symptoms of COVID-19 and influenza (flu) are similar, wherein, patients experience fever, cough, sore throat, fatigue and body aches.

However, an important difference between the two viruses is the speed of transmission. The COVID-19 virus has a longer incubation period as compared to influenza. Additionally, influenza has a shorter serial interval (time between successive cases) than the COVID-19 virus. Lastly, the mortality rate of COVID-19 is higher than that of influenza.

With the ongoing corona virus pandemic, the need for influenza diagnostics tests and related testing has shot up dramatically, which is eventually surging the growth of the global influenza diagnostics market.

Commercial Availability of Improved Diagnostic Tests for Influenza Infection

Rapid molecular assays are a new kind of molecular influenza diagnostic test with specificity and high sensitivity that are major developments in influenza diagnostics over recent years. Reverse transcription polymerase chain reaction (RT-PCR) and Nucleic acid detection tests have greatly improved the ability to detect respiratory viruses. Additionally, molecular tests for influenza are mainly focused on detection of specific known pathogens by NATs. NATs have several advantages over other existing diagnostic tools. They potentially can detect low levels of all-known influenza pathogens in clinical specimens, do not depend on the viability of the target microbe, and can provide results within a clinically relevant time frame. However, commercial rapid influenza diagnostic tests are mostly used method for influenza detection owing to its ability to detect influenza viruses within 15 minutes with low to moderate sensitivity and high specificity.

Regional Analysis of Influenza Diagnostics Market

North America and Europe currently hold more than 60% of the global influenza diagnostics market. The high prevalence of respiratory disease such as seasonal flu are propelling the demand for influenza diagnostics test in North America. However, East Asia and South Asia are poised for significant growth over the forecast period owing to factors such as large population base, increase burden of infectious disease, and wide use of rapid influenza diagnostic tests. Increased R&D investments and government initiatives are expected to boost the demand for influenza diagnosis in these regions.

Analysts’ Viewpoint

An extensive analysis of the influenza diagnostics market has brought our analysts to a conclusion that, the market is growing at a significant pace. Currently, rapid influenza detection tests is the target segment for major players, hence this segment dominates the global influenza diagnostics market by test type in term of market growth. Europe and North America collectively gain more than 60% of revenue share due to high adoption of influenza diagnostics test in these region. Emerging countries such as Brazil, china, and India are expected to offer lucrative opportunities for the Proteomic market growth owing to increasing awareness and initiative by local government for research and development in disease diagnostics.

Influenza Diagnostics Market - Scope of the Report

The latest publication by Persistence Market Research (PMR) on the global influenza diagnostics market evaluates the opportunities and current market landscape, and provides detailed analysis and updates about corresponding sections affecting the global influenza diagnostics market. The study offers detailed insights on key market dynamics, which includes the drivers, restraints, trends, and opportunities in the influenza diagnostics market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2020-2030.

Important indicators for successful growth in the influenza diagnostics market are presented in this comprehensive report, including Year-on-Year (Y-o-Y) growth analysis of the market and compounded annual growth rate (CAGR), which are described in an exhaustive way in PMR's research. This research study can support readers in knowing the demand for influenza diagnostics and quantitative development opportunities during the study period.

The research is beneficial for shareholders in influenza diagnostics, including influenza diagnostics market investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the influenza diagnostics market. The insights and wisdom presented in PMR’s study can be leveraged by shareholders in the influenza diagnostics market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics as well as information linked to macro- as well as micro-economic variables affecting the business scenario in the influenza diagnostics market are also included in the study. Depending on potential developments in the influenza diagnostics market, substantive insights are also encountered in this report. Additionally, by virtue of the data submitted in this report, minor companies and new entrants in the influenza diagnostics industry can make suitable business choices to achieve traction in the influenza diagnostics market.

Key Segments of Influenza Diagnostics Market

PMR’s study on the influenza diagnostics market offers information divided into five important segments— test type, type of flu, end user, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.


  • Molecular Diagnostic Tests
    • RT-PCR
    • LAMP
    • NASBA
  • Traditional Diagnostic Tests
    • Rapid Influenza Detection Tests
    • Serological Assays
    • Direct Fluorescent Antibodies
    • Viral Culture
    • H1N1 Influenza A Virus Identification Kits
    • Immunoassay Kits
    • Immunofluorescence Antibody Assays

Type of Flu

  • Type A Flu
  • Type B Flu
  • Type C Flu

End User

  • Hospitals
  • Diagnostic Laboratories
  • Research and Academic Institutes
  • Contract Research Organizations (CROs) 


  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa (MEA)

Key Questions Answered in PMR’s Influenza Diagnostics Market Report

  • Which regions will continue to remain the most profitable regional markets for influenza diagnostics market players?
  • Which factors will induce a change in the demand for influenza diagnostics during the assessment period?
  • How will changing trends impact the influenza diagnostics market?
  • How can market players capture the low-hanging opportunities in the influenza diagnostics market in developed regions?
  • What are the winning strategies of stakeholders in the influenza diagnostics market to upscale their position in this landscape?
  • What are the restraints that investors need to be aware of and tackle while investing in the influenza diagnostics market?
  • What are the developmental trends in influenza diagnostics sectors that will impact the market?
  • How can businesses in the influenza diagnostics market avail the growth opportunities in developed and emerging sectors?

Influenza Diagnostics Market: Research Methodology

In PMR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the influenza diagnostics market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the influenza diagnostics market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the influenza diagnostics market, and makes PMR’s projections on the growth prospects of the influenza diagnostics market more accurate and reliable.

Companies covered in Influenza Diagnostics Market Report

  • Abbott Laboratories
  • Endress+Hauser (Analytik Jena AG)
  • Becton, Dickinson and Company
  • Biocartis
  • bioMérieux Inc
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd
  • GenMark Diagnostics, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc
  • Quidel Corporation
  • Thermo Fisher Scientific Inc.
  • Hologic

Influenza Diagnostics Market

Back To Top